New Zealand - English - Medsafe (Medicines Safety Authority)

colgate-palmolive limited (nz) - sodium fluoride 0.22%{relative} equivalent to 1000 ppm fluoride ion; triclosan 0.3%{relative} - toothpaste - active: sodium fluoride 0.22%{relative} equivalent to 1000 ppm fluoride ion triclosan 0.3%{relative}

New Zealand - English - Medsafe (Medicines Safety Authority)

colgate-palmolive limited (nz) - sodium fluoride 0.22%{relative} equivalent to fluoride ion 1000 ppm; triclosan 0.3%{relative} - toothpaste - active: sodium fluoride 0.22%{relative} equivalent to fluoride ion 1000 ppm triclosan 0.3%{relative}

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - sodium fluoride 0.221%{relative} equivalent to 1000 ppm fluoride ion - toothpaste - 0.221% w/w - active: sodium fluoride 0.221%{relative} equivalent to 1000 ppm fluoride ion

United States - English - NLM (National Library of Medicine)

hto nevada inc. - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - fluoride ion 0.5 mg - for once daily, self-administered, systemic use as a dental caries preventive in pediatric patients.  it has been established that ingestion of fluoridated drinking water ( 1 ppm f ) during the period of tooth development results in a significant decrease in the incidence of dental caries.  kirkman's 1.1 mg sodium fluoride tablets were developed to provide systemic fluoride for use as a supplement in pediatric patients form 6 months to 16 years of age living in areas where the drinking water fluoride content does not exceed 0.6 ppm (f). krikman's 1.1 mg sodium fluoride tablets, are contraindicated when the fluoride content of drinking water is 0.6 ppm (f) or more and should not be administered to pediatric patients under the age of 6 months.  do not administer fluoride (any strength) to pediatric patients under age 6 months. the use of kirkman's 1.1 mg sodium fluoride tablets as a caries preventive in pediatric age groups 6 months to 16 years is supported by evidence from adequate and well-controlled studies

United States - English - NLM (National Library of Medicine)

hto nevada inc. - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - for once daily, self-administered, systemic use as a dental caries preventive in pediatric patients.  it has been established that ingestion of fluoridated drinking water ( 1 ppm f ) during the period of tooth development results in a significant decrease in the incidence of dental caries.  kirkman's 2.21 mg sodium fluoride tablets were developed to provide systemic fluoride for use as a supplement in pediatric patients form 6 months to 16 years of age living in areas where the drinking water fluoride content does not exceed 0.6 ppm (f). krikman's 2.21 mg sodium fluoride tablets, are contraindicated when the fluoride content of drinking water is 0.6 ppm (f) or more and should not be administered to pediatric patients under the age of 6 months.  do not administer fluoride (any strength) to pediatric patients under age 6 months. the use of kirkman's 2.21 mg sodium fluoride tablets as a caries preventive in pediatric age groups 6 months to 16 years is supported by evidence from adequate and well-controlled studi

Israel - English - Ministry of Health

teva medical marketing ltd. - sodium chloride - solution for infusion - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

Israel - English - Ministry of Health

teva medical marketing ltd. - sodium chloride - solution for infusion - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

United States - English - NLM (National Library of Medicine)

oral-b laboratories - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - fluoride ion 11 mg in 1 g - pediatric use:  the use of fluoride solutions, gels, and foams containing up to 1.23 % fluoride ion as caries preventives in pediatric patients aged 6 to 16 years is supported by clinical studies in students aged 6 to 12 years (1,2). safety and effectiveness in pediatric patients below the age of 6 years has not been established. please refer to contraindications and warnings sections.

United States - English - NLM (National Library of Medicine)

direct rx - rabeprazole sodium (unii: 3l36p16u4r) (rabeprazole - unii:32828355ll) - rabeprazole sodium 20 mg - 1.1 healing of erosive or ulcerative gerd in adults rabeprazole sodium delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (gerd). for those patients who have not healed after 8 weeks of treatment, an additional 8-week course of rabeprazole sodium delayed-release tablets may be considered. 1.2 maintenance of healing of erosive or ulcerative gerd in adults rabeprazole sodium delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (gerd maintenance). controlled studies do not extend beyond 12 months. 1.3 treatment of symptomatic gerd in adults rabeprazole sodium delayed-release tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with gerd in adults for up to 4 weeks. 1.4 healing of duodenal ulcers in adults rabep

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.